Guidance, NICE advice and quality standards in development

Showing 171 to 180 of 373

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]	Technology appraisal guidance	TBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]	Technology appraisal guidance	TBC
Linzagolix for treating pain caused by endometriosis [ID6357]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]	Technology appraisal guidance	11 December 2024
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC